prednisone has been researched along with Inclusion Body Myopathy, Sporadic in 13 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "IVIg combined with prednisone for a 3-month period was not effective in IBM." | 2.70 | A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. ( Cupler, E; Dalakas, MC; Fujii, M; Koffman, B; Sivakumar, K; Spector, S, 2001) |
| "We report favorable results of the long term use of mycophenolate in the treatment of three patients with myasthenia gravis (MG), two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with secondary polymyositis (PM), and one patient with inclusion body myositis (IBM)." | 2.70 | Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. ( Bradley, WG; Mowzoon, N; Sussman, A, 2001) |
| "We report a patient with systemic lupus erythematosus (SLE) and secondary Sjögren's syndrome (SS) who developed inclusion body myositis (IBM) which, contrary to the typical presentation of this disorder, was symmetrical in nature although the diagnosis was only made after electron microscopy was performed." | 2.42 | Inclusion body myositis in connective tissue disorders: case report and review of the literature. ( Derk, CT; Kenyon, L; Mandel, S; Vivino, FB, 2003) |
| "Prednisone dose was gradually decreased to 5." | 1.43 | Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis. ( Pérez-Berenguer, JL; Varela-Rosario, N; Vilá, LM, 2016) |
| "In sporadic inclusion body myositis (IBM), inflammation and accumulation of β-amyloid-associated molecules cause muscle fiber damage." | 1.38 | Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle. ( Creus, K; Dalakas, MC; Raju, R; Schmidt, J; Sehmisch, S; Voss, J; Zschüntzsch, J, 2012) |
| "The sporadic inclusion body myositis weakness composite index, which correlated with grip strength (correlation coefficient: 0." | 1.37 | Long-term observational study of sporadic inclusion body myositis. ( Allenbach, Y; Benveniste, O; Brady, S; Dubourg, O; Eymard, B; Freebody, J; Guiguet, M; Herson, S; Hilton-Jones, D; Leite, MI; Maisonobe, T; Squier, W; Stojkovic, T, 2011) |
| "Treatment with prednisone and methotrexate resulted in complete remission of symptoms." | 1.35 | Dermatomyositis with inclusion body myositis pathology. ( Iverson, D; Layzer, R; Lee, HS; Margeta, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, C | 1 |
| Lee, JS | 1 |
| Cool, CD | 1 |
| Wicklund, MP | 1 |
| Fischer, A | 1 |
| Varela-Rosario, N | 1 |
| Pérez-Berenguer, JL | 1 |
| Vilá, LM | 1 |
| Layzer, R | 1 |
| Lee, HS | 1 |
| Iverson, D | 1 |
| Margeta, M | 1 |
| Benveniste, O | 1 |
| Guiguet, M | 1 |
| Freebody, J | 1 |
| Dubourg, O | 1 |
| Squier, W | 1 |
| Maisonobe, T | 1 |
| Stojkovic, T | 1 |
| Leite, MI | 1 |
| Allenbach, Y | 1 |
| Herson, S | 2 |
| Brady, S | 1 |
| Eymard, B | 2 |
| Hilton-Jones, D | 1 |
| Zschüntzsch, J | 1 |
| Voss, J | 1 |
| Creus, K | 1 |
| Sehmisch, S | 1 |
| Raju, R | 1 |
| Dalakas, MC | 2 |
| Schmidt, J | 1 |
| Derk, CT | 1 |
| Vivino, FB | 1 |
| Kenyon, L | 1 |
| Mandel, S | 1 |
| Voermans, NC | 1 |
| Vaneker, M | 1 |
| Hengstman, GJ | 2 |
| ter Laak, HJ | 2 |
| Zimmerman, C | 1 |
| Schelhaas, HJ | 1 |
| Zwarts, MJ | 1 |
| Hoogendijk, JE | 1 |
| Bijlsma, JW | 1 |
| van Engelen, BG | 2 |
| Lindeman, E | 1 |
| van Royen-Kerkhof, A | 1 |
| de Rie, MA | 1 |
| de Visser, M | 1 |
| Jennekens, FG | 1 |
| Pruitt, JN | 1 |
| Showalter, CJ | 1 |
| Engel, AG | 1 |
| Koffman, B | 1 |
| Fujii, M | 1 |
| Spector, S | 1 |
| Sivakumar, K | 1 |
| Cupler, E | 1 |
| Mowzoon, N | 1 |
| Sussman, A | 1 |
| Bradley, WG | 1 |
| van Venrooij, BG | 1 |
| Cherin, P | 1 |
| Pelletier, S | 1 |
| Teixeira, A | 1 |
| Laforet, P | 1 |
| Simon, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study[NCT00079768] | Phase 2 | 20 participants | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for prednisone and Inclusion Body Myopathy, Sporadic
| Article | Year |
|---|---|
Inclusion body myositis in connective tissue disorders: case report and review of the literature.
Topics: Biopsy, Needle; Drug Therapy, Combination; Female; Humans; Immunohistochemistry; Lupus Erythematosus | 2003 |
Primary respiratory failure in inclusion body myositis.
Topics: Anti-Inflammatory Agents; Biopsy; Electromyography; Female; Humans; Middle Aged; Muscle Weakness; My | 2004 |
2 trials available for prednisone and Inclusion Body Myopathy, Sporadic
| Article | Year |
|---|---|
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Immunoglobulins, Intravenous; Muscles; | 2001 |
Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Chronic Disease; Drug Therapy, Combination | 2001 |
9 other studies available for prednisone and Inclusion Body Myopathy, Sporadic
| Article | Year |
|---|---|
Development of Autoimmune Interstitial Lung Disease in a Patient with Inclusion Body Myositis.
Topics: Autoimmune Diseases; Biopsy, Needle; Follow-Up Studies; Humans; Immunohistochemistry; Immunosuppress | 2019 |
Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis.
Topics: Aged; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Methotrexate; Myositi | 2016 |
Dermatomyositis with inclusion body myositis pathology.
Topics: Anti-Inflammatory Agents; Antigens, CD; Dermatologic Agents; Dermatomyositis; Humans; Male; Methotre | 2009 |
Long-term observational study of sporadic inclusion body myositis.
Topics: Aged; Azathioprine; Cohort Studies; Disability Evaluation; Female; Humans; Immunoglobulins, Intraven | 2011 |
Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.
Topics: Amyloid beta-Peptides; Biopsy; Cells, Cultured; Chemokines; Cytokines; Drug Therapy, Combination; Hu | 2012 |
[The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis'].
Topics: Anti-Inflammatory Agents; Dermatomyositis; Dose-Response Relationship, Drug; Humans; Myositis, Inclu | 2005 |
Sporadic inclusion body myositis: counts of different types of abnormal fibers.
Topics: Adult; Aged; Aged, 80 and over; Congo Red; Female; Humans; Male; Middle Aged; Myositis, Inclusion Bo | 1996 |
Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone.
Topics: Administration, Oral; Aged; Histidine-tRNA Ligase; Humans; Male; Myositis, Inclusion Body; Prednison | 2001 |
Intravenous immunoglobulin for dysphagia of inclusion body myositis.
Topics: Aged; Anti-Inflammatory Agents; Deglutition Disorders; Esophagus; Female; Humans; Immunoglobulins, I | 2002 |